Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

Patients with severe asthma required fewer steroid bursts with tezepelumab-ekko, according to a poster presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization ...

showed a 27% reduction in the risk of death versus placebo AstraZeneca's Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited ...

In a world where healthcare is moving fast, HCG is moving faster. Always ahead of the curve, HCG is spearheading the charge to turn scientific potential into real-world impact.

AstraZeneca and Amgen funded a Phase 3 clinical trial of tezepelumab, led by the Scottish Center for Respiratory Research at the University of Dundee in collaboration with Eastern Virginia Medical ...

After several months, inflammatory disease medication Dupixent has finally reclaimed its spot atop the rankings for over-the-counter (OTC) and Rx brand marketing on TV. The Regeneron and Sanofi brand, ...

The study met its primary endpoint, but analysts compared the results unfavorably to the data on Dupixent. Adjusted for placebo, 19.1% of people on rocatinlimab had 75% improvement in eczema area ...

Tezepelumab reduced the size of nasal polyps and the severity of nasal congestion in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, in a placebo-controlled study ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...

Positive results from the ADEPT Phase II/III study indicate that Dupixent (dupilumab) may be effective in treating moderate-to-severe bullous pemphigoid (BP). The findings were presented at the 2025 ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent in adults with moderate-to-severe ...